The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1385
March 5, 2012
View Complete Issue         Table of Contents 2019 
Glucarpidase (Voraxaze) for Methotrexate Toxicity
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Glucarpidase (Voraxaze) for Methotrexate Toxicity
March 5, 2012 (Issue: 1385)
The FDA has approved glucarpidase (Voraxaze – BTG International) for treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function. Glucarpidase has...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Glucarpidase (Voraxaze) for Methotrexate Toxicity
Article code: 1385c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.